COVID-flu joint booster shot possible in late 2023, Moderna says

Moderna aims to roll out a combined COVID-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm says, hoping a joint shot will encourage people to get an annual vaccination.

The single vaccine for COVID-19, influenza and respiratory syncytial virus — a common virus that causes the cold, but can be more serious for infants and elderly people — could appear on the market before 2024.

“Best-case scenario will be the fall of ’23,” Moderna chief executive Stephane Bancel tells a virtual World Economic Forum roundtable session.

“I don’t think it would happen in every country, but we believe it’s possible to happen in some countries next year. Our goal is to be able to have a single annual booster so that we don’t have compliance issues where people don’t want to get two to three shots a winter, but to get one dose.”

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: [email protected]
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.